Literature DB >> 20585027

MR angiogenesis imaging with Robo4- vs. alphaVbeta3-targeted nanoparticles in a B16/F10 mouse melanoma model.

Kent S Boles1, Anne H Schmieder, Alexander W Koch, Richard A D Carano, Yan Wu, Shelton D Caruthers, Raymond K Tong, Scott Stawicki, Grace Hu, Michael J Scott, Huiying Zhang, Benton A Reynolds, Samuel A Wickline, Gregory M Lanza.   

Abstract

The primary objective of this study was to utilize MR molecular imaging to compare the 3-dimensional spatial distribution of Robo4 and α(V)β(3)-integrin as biosignatures of angiogenesis, in a rapidly growing, syngeneic tumor. B16-F10 melanoma-bearing mice were imaged with magnetic resonance (MR; 3.0 T) 11 d postimplantation before and after intravenous administration of either Robo4- or α(V)β(3)-targeted paramagnetic nanoparticles. The percentage of MR signal-enhanced voxels throughout the tumor volume was low and increased in animals receiving α(V)β(3)- and Robo4-targeted nanoparticles. Neovascular signal enhancement was predominantly associated with the tumor periphery (i.e., outer 50% of volume). Microscopic examination of tumors coexposed to the Robo4- and α(V)β(3)-targeted nanoparticles corroborated the MR angiogenesis mapping results and further revealed that Robo4 expression generally colocalized with α(V)β(3)-integrin. Robo4- and α(V)β(3)-targeted nanoparticles were compared to irrelevant or nontargeted control groups in all modalities. These results suggest that α(V)β(3)-integrin and Robo4 are useful biomarkers for noninvasive MR molecular imaging in syngeneic mouse tumors, but α(V)β(3)-integrin expression was more detectable by MR at 3.0 T than Robo4. Noninvasive, neovascular assessments of the MR signal of Robo4, particularly combined with α(V)β(3)-integrin expression, may help define tumor character prior to and following cancer therapy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20585027      PMCID: PMC3066028          DOI: 10.1096/fj.10-157933

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  42 in total

1.  Targeted nanoparticles for quantitative imaging of sparse molecular epitopes with MRI.

Authors:  Anne M Morawski; Patrick M Winter; Kathryn C Crowder; Shelton D Caruthers; Ralph W Fuhrhop; Michael J Scott; J David Robertson; Dana R Abendschein; Gregory M Lanza; Samuel A Wickline
Journal:  Magn Reson Med       Date:  2004-03       Impact factor: 4.668

2.  Endothelial alpha(v)beta3 integrin-targeted fumagillin nanoparticles inhibit angiogenesis in atherosclerosis.

Authors:  Patrick M Winter; Anne M Neubauer; Shelton D Caruthers; Thomas D Harris; J David Robertson; Todd A Williams; Anne H Schmieder; Grace Hu; John S Allen; Elizabeth K Lacy; Huiying Zhang; Samuel A Wickline; Gregory M Lanza
Journal:  Arterioscler Thromb Vasc Biol       Date:  2006-07-06       Impact factor: 8.311

3.  Molecular imaging of angiogenesis in early-stage atherosclerosis with alpha(v)beta3-integrin-targeted nanoparticles.

Authors:  Patrick M Winter; Anne M Morawski; Shelton D Caruthers; Ralph W Fuhrhop; Huiying Zhang; Todd A Williams; John S Allen; Elizabeth K Lacy; J David Robertson; Gregory M Lanza; Samuel A Wickline
Journal:  Circulation       Date:  2003-10-13       Impact factor: 29.690

4.  Noninvasive imaging of myocardial angiogenesis following experimental myocardial infarction.

Authors:  David F Meoli; Mehran M Sadeghi; Svetlana Krassilnikova; Brian N Bourke; Frank J Giordano; Donald P Dione; Haili Su; D Scott Edwards; Shuang Liu; Thomas D Harris; Joseph A Madri; Barry L Zaret; Albert J Sinusas
Journal:  J Clin Invest       Date:  2004-06       Impact factor: 14.808

5.  19F magnetic resonance imaging for stem/progenitor cell tracking with multiple unique perfluorocarbon nanobeacons.

Authors:  Kathryn C Partlow; Junjie Chen; Jason A Brant; Anne M Neubauer; Todd E Meyerrose; Michael H Creer; Jan A Nolta; Shelton D Caruthers; Gregory M Lanza; Samuel A Wickline
Journal:  FASEB J       Date:  2007-02-06       Impact factor: 5.191

6.  In vitro demonstration using 19F magnetic resonance to augment molecular imaging with paramagnetic perfluorocarbon nanoparticles at 1.5 Tesla.

Authors:  Shelton D Caruthers; Anne M Neubauer; Frank D Hockett; Rolf Lamerichs; Patrick M Winter; Michael J Scott; Patrick J Gaffney; Samuel A Wickline; Gregory M Lanza
Journal:  Invest Radiol       Date:  2006-03       Impact factor: 6.016

7.  Minute dosages of alpha(nu)beta3-targeted fumagillin nanoparticles impair Vx-2 tumor angiogenesis and development in rabbits.

Authors:  Patrick M Winter; Anne H Schmieder; Shelton D Caruthers; Jeffery L Keene; Huiying Zhang; Samuel A Wickline; Gregory M Lanza
Journal:  FASEB J       Date:  2008-03-24       Impact factor: 5.191

Review 8.  Role of angiogenesis in tumor growth and metastasis.

Authors:  Judah Folkman
Journal:  Semin Oncol       Date:  2002-12       Impact factor: 4.929

9.  Involvement of integrins alpha v beta 3 and alpha v beta 5 in ocular neovascular diseases.

Authors:  M Friedlander; C L Theesfeld; M Sugita; M Fruttiger; M A Thomas; S Chang; D A Cheresh
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-03       Impact factor: 11.205

Review 10.  Slits and Roundabouts in cancer, tumour angiogenesis and endothelial cell migration.

Authors:  John A Legg; John M J Herbert; Patricia Clissold; Roy Bicknell
Journal:  Angiogenesis       Date:  2008-02-09       Impact factor: 9.596

View more
  17 in total

1.  Vascular density and endothelial cell expression of integrin alpha v beta 3 and E-selectin in murine tumours.

Authors:  Johanne Seguin; Céline Nicolazzi; Nathalie Mignet; Daniel Scherman; Guy G Chabot
Journal:  Tumour Biol       Date:  2012-06-07

Review 2.  Vascular targeting of nanoparticles for molecular imaging of diseased endothelium.

Authors:  Prabhani U Atukorale; Gil Covarrubias; Lisa Bauer; Efstathios Karathanasis
Journal:  Adv Drug Deliv Rev       Date:  2016-09-15       Impact factor: 15.470

3.  Imaging of brain tumors with paramagnetic vesicles targeted to phosphatidylserine.

Authors:  Patrick M Winter; John Pearce; Zhengtao Chu; Christopher M McPherson; Ray Takigiku; Jing-Huei Lee; Xiaoyang Qi
Journal:  J Magn Reson Imaging       Date:  2014-05-06       Impact factor: 4.813

Review 4.  Applications of nanotechnology in dermatology.

Authors:  Lisa A DeLouise
Journal:  J Invest Dermatol       Date:  2012-01-05       Impact factor: 8.551

Review 5.  Targeted nanotechnology for cancer imaging.

Authors:  Randall Toy; Lisa Bauer; Christopher Hoimes; Ketan B Ghaghada; Efstathios Karathanasis
Journal:  Adv Drug Deliv Rev       Date:  2014-08-09       Impact factor: 15.470

6.  Nanotechnology for cancer treatment.

Authors:  William H Gmeiner; Supratim Ghosh
Journal:  Nanotechnol Rev       Date:  2015-04       Impact factor: 7.848

7.  Delivery of a Protease-Activated Cytolytic Peptide Prodrug by Perfluorocarbon Nanoparticles.

Authors:  Andrew P Jallouk; Rohun U Palekar; Jon N Marsh; Hua Pan; Christine T N Pham; Paul H Schlesinger; Samuel A Wickline
Journal:  Bioconjug Chem       Date:  2015-07-02       Impact factor: 4.774

Review 8.  Design of a novel class of protein-based magnetic resonance imaging contrast agents for the molecular imaging of cancer biomarkers.

Authors:  Shenghui Xue; Jingjuan Qiao; Fan Pu; Mathew Cameron; Jenny J Yang
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2013-01-17

9.  Suppression of inflammation in a mouse model of rheumatoid arthritis using targeted lipase-labile fumagillin prodrug nanoparticles.

Authors:  Hui-Fang Zhou; Huimin Yan; Angana Senpan; Samuel A Wickline; Dipanjan Pan; Gregory M Lanza; Christine T N Pham
Journal:  Biomaterials       Date:  2012-08-24       Impact factor: 12.479

Review 10.  Molecular imaging for cancer diagnosis and surgery.

Authors:  Timon Hussain; Quyen T Nguyen
Journal:  Adv Drug Deliv Rev       Date:  2013-09-22       Impact factor: 15.470

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.